SCHEMBL72357

SCHEMBL72357

CCOC(=O)[C@H]1CC[C@H](OC(C(=O)OC(C)(C)C)(N2CCCC2)N2CCN(C)C(=O)C2)CC1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.39
TSHR P16473 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 2/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 2/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72358 1.00 ALDH1A1 (0.39) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL73422 0.88 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL73423 0.88 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL70540 0.87 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL71854 0.87 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL72711 0.87 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL70753 0.87 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
SCHEMBL72710 0.87 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
Hydrochloric Acid SCHEMBL72343 0.87 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB
Hydrochloric Acid SCHEMBL72344 0.87 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885TSHR 2972/4885MEN1 4254/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885TSHR 3047/4885MEN1 4337/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885TSHR 3028/4885MEN1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.